+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Hairy Cell Leukemia Therapeutics Market 2019-2023 - Product Image

Global Hairy Cell Leukemia Therapeutics Market 2019-2023

  • ID: 4808298
  • Report
  • July 2019
  • Region: Global
  • 129 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • AstraZeneca Plc
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co. Inc.
  • Mylan NV
  • Pfizer Inc.
  • MORE
Global Hairy Cell Leukemia Therapeutics Market: About this market

Hairy cell leukemia is a rare, slow-growing subtype of leukemia, which accounts for about 2% of the total cases of leukemia. The hairy cell leukemia therapeutics analysis considers sales from both chemotherapies and targeted therapy. Our analysis also considers the sales of hairy cell leukemia therapeutics in North America, Europe, Asia, and the rest of the world (ROW). In 2018, the chemotherapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the increasing prevalence of leukemia, including hairy cell leukemia, will play a significant role in the chemotherapy segment to maintain its market position. Also, our global hairy cell leukemia therapeutics market report looks at factors such as increased exposure to hazardous substances leading to hairy cell leukemia, growing geriatric population, strategic alliances. However, limited patient pool, adverse effects of chemotherapy drugs, difficulty in diagnosis may hamper the growth of the hairy cell leukemia therapeutics industry over the forecast period.

Global Hairy Cell Leukemia Therapeutics Market: Overview

Increasing exposure to hazardous substances leading to hairy cell leukemia

Exposure to such hazardous substances can happen due to various types of occupations such as farming, working in manufacturing plants dealing with hazardous chemicals and fumes, and working in coal mines, cement- and gravel-producing plants. Exposure to chemical fertilizers and pesticides is continuously increasing as the lack of nutrients in the soil has increased the use of fertilizers to provide required nutrients and to improve agriculture yields. Thus, to meet the food demand of the ever-increasing population, chemical fertilizers are increasingly used, which is expected to increase the prevalence of hairy cell leukemia which, in turn, will lead the expansion of the global hairy cell leukemia therapeutics market at a CAGR of over 6% during the forecast period.

Advent of novel therapies

The global hairy cell leukemia therapeutics market has been witnessing some advances in research since the beginning of the 21st century, which have led to the launch of a few novel therapies for the treatment of hairy cell leukemia and other hematologic malignancies. The strong prevalence of various types of blood cancer at the global level has necessitated the need for the development of advanced therapies, such as kinase inhibitors and gene therapies, to treat such conditions. Such advents of novel therapies are likely to offset the challenges posed by the adverse effects of chemotherapy drugs in the future: which will contribute to the growth of the market during the forecast period.

Competitive Landscape

With the presence of several major players, the global hairy cell leukemia therapeutics market is concentrated. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading hairy cell leukemia therapeutics manufacturers, that include AstraZeneca Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Mylan NV, and Pfizer Inc.

Also, the hairy cell leukemia therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AstraZeneca Plc
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co. Inc.
  • Mylan NV
  • Pfizer Inc.
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • Chemotherapy - Market size and forecast 2018-2023
  • Targeted therapy - Market size and forecast 2018-2023
  • Market opportunity by product
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS
  • Increasing research grants for blood cancers
  • Advent of novel therapies
  • Special drug designations
PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca Plc
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Mylan NV
  • Pfizer Inc.
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits:
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Chemotherapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Chemotherapy - Year-over-year growth 2019-2023 (%)
Exhibit 22: Targeted therapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Targeted therapy - Year-over-year growth 2019-2023 (%)
Exhibit 24: Patient assistance programs
Exhibit 25: Market opportunity by product
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
Exhibit 31: Top 3 countries in North America
Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in Europe
Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Proportion of geriatric population in Asia 2009 and 2018
Exhibit 37: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in Asia
Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 40: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 41: Top 3 countries in ROW
Exhibit 42: Key leading countries
Exhibit 43: Market opportunity
Exhibit 44: Growth in geriatric population 2014-2018 (%)
Exhibit 45: Side effects of chemotherapy drugs used for treatment of hairy cell leukemia
Exhibit 46: Impact of drivers and challenges
Exhibit 47: Drug designations
Exhibit 48: Vendor landscape
Exhibit 49: Landscape disruption
Exhibit 50: Vendors covered
Exhibit 51: Vendor classification
Exhibit 52: Market positioning of vendors
Exhibit 53: AstraZeneca Plc - Vendor overview
Exhibit 54: AstraZeneca Plc - Business segments
Exhibit 55: AstraZeneca Plc - Organizational developments
Exhibit 56: AstraZeneca Plc - Geographic focus
Exhibit 57: AstraZeneca Plc - Key offerings
Exhibit 58: AstraZeneca Plc - Key customers
Exhibit 59: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 60: F. Hoffmann-La Roche Ltd. - Product segments
Exhibit 61: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 62: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 63: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 64: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 65: F. Hoffmann-La Roche Ltd. - Key customers
Exhibit 66: Merck & Co. Inc. - Vendor overview
Exhibit 67: Merck & Co. Inc. - Business segments
Exhibit 68: Merck & Co. Inc. - Organizational developments
Exhibit 69: Merck & Co. Inc. - Geographic focus
Exhibit 70: Merck & Co. Inc. - Segment focus
Exhibit 71: Merck & Co. Inc. - Key offerings
Exhibit 72: Merck & Co. Inc. - Key customers
Exhibit 73: Mylan NV - Vendor overview
Exhibit 74: Mylan NV - Product segments
Exhibit 75: Mylan NV - Organizational developments
Exhibit 76: Mylan NV - Geographic focus
Exhibit 77: Mylan NV - Segment focus
Exhibit 78: Mylan NV - Key offerings
Exhibit 79: Mylan NV - Key customers
Exhibit 80: Pfizer Inc. - Vendor overview
Exhibit 81: Pfizer Inc. - Business segments
Exhibit 82: Pfizer Inc. - Organizational developments
Exhibit 83: Pfizer Inc. - Geographic focus
Exhibit 84: Pfizer Inc. - Segment focus
Exhibit 85: Pfizer Inc. - Key offerings
Exhibit 86: Pfizer Inc. - Key customers
Exhibit 87: Validation techniques employed for market sizing
Exhibit 88: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • AstraZeneca Plc
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co. Inc.
  • Mylan NV
  • Pfizer Inc.
  • MORE
The following companies are recognised as the key players in the global hairy cell leukemia therapeutics market: AstraZeneca Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Mylan NV, and Pfizer Inc.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the advent of novel therapies.”

According to the report, one of the major drivers for this market is the increased exposure to hazardous substances leading to hairy cell leukemia.

Further, the report states that one of the major factors hindering the growth of this market is the limited patient pool.

The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • AstraZeneca Plc
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co. Inc.
  • Mylan NV
  • Pfizer Inc.
Note: Product cover images may vary from those shown
Adroll
adroll